Charcot-Marie-Tooth Disease Clinical Trial
Official title:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with Charcot-Marie-Tooth Disease Type 1 and Type X (CMT1 and CMTX), to be conducted in two parts. Part 1 is non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.
Part 1 (non-randomized, open-label, dose-escalation) Part 1 will consist of up to 3 cohorts of 6 patients each and will evaluate multiple ascending dose levels of ACE-083 administered bilaterally once every 3 weeks for up to 5 doses in the tibialis anterior (TA) muscle. Patients in each cohort will be enrolled in a 4-week screening period before beginning treatment. Part 2 (randomized, double-blind, placebo-controlled) Prior to the initiation of Part 2, a review of safety and efficacy data from Part 1 will be conducted by the Safety Review Team (SRT) to determine the recommended dose level (maximum 250 mg/muscle). A total of up to 40 new patients may be enrolled and randomized (1:1 randomization) to receive either ACE 083 (n=20) or placebo (n=20) bilaterally by injection into both TA muscles once every 3 weeks for up to 17 doses. Study duration for Parts 1 and 2 for each patient will be approximately 24 weeks, including a 4-week screening period, a 12-week treatment period, and an 8-week follow-up period after the last dose. Study duration for Part 2 will be 15 months, including 4-week screening, 6 months double blind placebo-controlled, 6 months open-label and 8 week follow-up. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06203093 -
Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for iPSC Generation and Biobanking
|
||
Recruiting |
NCT03782883 -
The Impact of Charcot-Marie-Tooth Disease in the Real World
|
||
Recruiting |
NCT02979145 -
Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)
|
N/A | |
Terminated |
NCT03254199 -
A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.
|
Phase 2 | |
Completed |
NCT02011204 -
Study of Electrical Impedance Myography (EIM) in ALS
|
N/A | |
Completed |
NCT00149045 -
Follow up and Observation of Charcot Marie Tooth Disease in Families
|
N/A | |
Completed |
NCT04786522 -
Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease
|
||
Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
Recruiting |
NCT05902351 -
Natural History Study for Charcot Marie Tooth Disease
|
||
Terminated |
NCT03943290 -
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
|
Phase 2 | |
Active, not recruiting |
NCT04762758 -
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
|
Phase 3 | |
Completed |
NCT02788734 -
Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies
|
N/A | |
Recruiting |
NCT02532244 -
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
|
||
Terminated |
NCT05827419 -
Hearing and Balance Disorders in Peripheral Neuropathy
|
||
Terminated |
NCT03810508 -
A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
|
||
Recruiting |
NCT04010188 -
A Registered Cohort Study on Charcot-Marie-Tooth Disease
|
||
Completed |
NCT00271635 -
Ascorbic Acid Treatment in CMT1A Trial (AATIC)
|
Phase 2 | |
Completed |
NCT03715283 -
Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care
|
N/A | |
Completed |
NCT02001038 -
Survey of Current Management of Orthopaedic Complications in CMT Patients
|
N/A | |
Not yet recruiting |
NCT01289704 -
Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A)
|
Phase 2/Phase 3 |